DAFTAR PUSTAKA

Agalioti, T., Giannou, A. D. & Stathopoulos, G. T., 2015. Pleural involvement in lung cancer. *Journal of thoracic disease*, *7*(6), 1021.

Allemani, C. *et al*, 2018. Global surveillance of trends in cancer survival 2000–14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. *The Lancet*, *391*(10125), pp.1023-1075.

Arslan, S.A. *et al*, 2019. Right predilection of lung cancer, does it affect oncologic outcome? Akciğer kanserinin sağ yerleşimli olma eğilimi onkolojik sonuçları etkiler mi?. *Acta Oncologica Turcica*, *52*(2), 232-237.

Barta, J.A., Powell, C.A. & Wisnivesky, J.P., 2019. Global epidemiology of lung cancer. *Annals of global health*, *85*(1).

Borczuk, A.C. ed., 2021. *WHO classification of tumours: Thoracic tumours*. International Agency for Research on Cancer.

Brainard, J. & Farver, C., 2019. The diagnosis of non-small cell lung cancer in the molecular era. *Modern Pathology*, *32*(1), 16-26.

Cainap, C., Balacescu, O., Cainap, S.S. & Pop, L.A., 2021. Next generation sequencing technology in lung cancer diagnosis. *Biology*, *10*(9), p.864.

Chen, Y. C. *et al*, 2004. Lung adenocarcinoma and human papillomavirus infection. *Cancer: Interdisciplinary International Journal of the American Cancer Society*, *101*(6), 1428-1436.

Cooper, W.A. *et al*, 2013. EGFR mutant-specific immunohistochemistry has high specificity and sensitivity for detecting targeted activating EGFR mutations in lung adenocarcinoma. *Journal of clinical pathology*, *66*(9), pp.744-748.

Duijm, M. *et al*, 2016. Dose and volume of the irradiated main bronchi and related side effects in the treatment of central lung tumors with stereotactic radiotherapy. In *Seminars in radiation oncology* (Vol. 26, No. 2, pp. 140-148). WB Saunders.

Duma, N., Santana-Davila, R. & Molina, J. R., 2019. Non–small cell lung cancer: epidemiology, screening, diagnosis, and treatment. In *Mayo Clinic Proceedings* (Vol. 94, No. 8, pp. 1623-1640). Elsevier.

El-Zammar, O.A., Zhang, S. & Katzenstein, A.L.A., 2009. Comparison of FISH, PCR, and immunohistochemistry in assessing EGFR status in lung adenocarcinoma and correlation with clinicopathologic features. *Diagnostic Molecular Pathology*, *18*(3), pp.133-137.

Er, T.K. *et al*, 2015. Increase EGFR mutations detection rate in lung adenocarcinoma by real-time PCR screening followed by direct sequencing. *Applied Immunohistochemistry & Molecular Morphology*, *23*(5), pp.343-348.

Ettinger, D. S. *et al*, 2022. Non–Small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology. *Journal of the National Comprehensive Cancer Network*, *20*(5), 497-530.

Fearon, K. C., Glass, D. J. & Guttridge, D. C., 2012. Cancer cachexia: mediators, signaling, and metabolic pathways. *Cell metabolism*, *16*(2), 153-166.

Fu, J. B., Kau, T. Y., Severson, R. K. & Kalemkerian, G. P., 2005. Lung cancer in women: analysis of the national Surveillance, Epidemiology, and End Results database. *Chest*, *127*(3), 768-777.

Gevaert, O. *et al*, 2017. Predictive radiogenomics modeling of EGFR mutation status in lung cancer. *Scientific reports*, *7*(1), 1-8.

Gridelli, C. *et al*, 2015. Non-small-cell lung cancer. *Nature reviews Disease primers*, *1*(1), 1-16.

Gristina, V. *et al*, 2020. The significance of epidermal growth factor receptor uncommon mutations in non-small cell lung cancer: A systematic review and critical appraisal. *Cancer Treatment Reviews*, *85*, 101994.

Hanafi, A. R. *et al*, 2020. Serum MiRNA as Predictive and Prognosis Biomarker in Advanced Stage Non-small Cell Lung Cancer in Indonesia. *Zhongguo fei ai za zhi = Chinese journal of lung cancer*, *23*(5), 321–332. https://doi.org/10.3779/j.issn.1009-3419.2020.104.02

Hao, P. *et al*, 2020. Lung adenocarcinoma diagnosis in one stage. *Neurocomputing*, *392*, 245-252.

Harsal, A., Suratman, E. & Tambunan, T., 2007. P1-038: Overview of lung cancer in Dharmais National Cancer Hospital, Jakarta, Indonesia. *Journal of Thoracic Oncology*, *2*(8), S564.

He, M. *et al*, 2012. EGFR Exon 19 Insertions: A New Family of Sensitizing EGFR Mutations in Lung Adenocarcinoma EGFR Exon 19 Insertions in Lung Adenocarcinoma. *Clinical cancer research*, 18(6), 1790-1797.

Herceg, Z. & Hainaut, P., 2007. Genetic and epigenetic alterations as biomarkers for cancer detection, diagnosis and prognosis. *Molecular oncology*, *1*(1), 26-41.

Heriyanto, D. S. *et al*, 2020. The prevalence of the EML4-ALK fusion gene in cytology specimens from patients with lung adenocarcinoma. *Pulmonary Medicine*, *2020*.

Hirsch, F. R. *et al*, 2003. Epidermal growth factor receptor in non–small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis. *Journal of clinical oncology*, *21*(20), 3798-3807.

Hutchinson, B. D., Shroff, G. S., Truong, M. T. & Ko, J. P., 2019. Spectrum of lung adenocarcinoma. In *Seminars in Ultrasound, CT and MRI* (Vol. 40, No. 3, pp. 255-264). WB Saunders.

Hsu, C. L. *et al*, 2012. Advanced non-small cell lung cancer in patients aged 45 years or younger: outcomes and prognostic factors. *BMC cancer*, *12*(1), 1-7.

Hsu, J. S. *et al*, 2014. Correlation between EGFR mutation status and computed tomography features in patients with advanced pulmonary adenocarcinoma. *Journal of thoracic imaging*, *29*(6), 357-363.

Ilonen, I., 2011. Non-small cell lung cancer: Studies on pathogenesis, tumour targeting and treatment outcomes.

Imyanitov, E.N. *et al*, 2016. Distribution of EGFR mutations in 10,607 Russian patients with lung cancer. *Molecular diagnosis & therapy*, *20*, pp.401-406.

Inamura, K., 2018. Clinicopathological characteristics and mutations driving development of early lung adenocarcinoma: tumor initiation and progression. *International journal of molecular sciences*, *19*(4), 1259.

International Agency for Research of Cancer (IARC), (2020). *GLOBOCAN 2020: Estimated Cancer Incidence, Mortality, and Prevalence Worldwide in 2020.* [online] Globocan.iarc.fr. Diakses pada bulan Desember 2022 melalui: https://gco.iarc.fr/today/data/factsheets/populations/360-indonesia-fact-sheets.pdf

Jimeno, A. & Hidalgo, M., 2006. Pharmacogenomics of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors. *Biochimica et Biophysica Acta (BBA)-Reviews on Cancer*, *1766*(2), 217-229.

Jorge, S. E. D. C., Kobayashi, S. S. & Costa, D. B., 2014. Epidermal growth factor receptor (EGFR) mutations in lung cancer: preclinical and clinical data. *Brazilian Journal of Medical and Biological Research*, *47*, 929-939.

Kaler, A. K. *et al*, 2023. Mutational Analysis of EGFR Mutations in Non-Small Cell Lung Carcinoma—An Indian Perspective of 212 Patients. *International Journal of Environmental Research and Public Health*, *20*(1), 758.

Kim, E. Y. *et al*, 2016. Compound EGFR mutation is frequently detected with co-mutations of actionable genes and associated with poor clinical outcome in lung adenocarcinoma. *Cancer biology & therapy*, *17*(3), 237-245.

Kim, T. J. *et al*, 2016. Radiologic characteristics of surgically resected non-small cell lung cancer with ALK rearrangement or EGFR mutations. *The Annals of thoracic surgery*, *101*(2), 473-480.

Kobayashi, Y. & Mitsudomi, T., 2016. Not all epidermal growth factor receptor mutations in lung cancer are created equal: perspectives for individualized treatment strategy. *Cancer science*, *107*(9), 1179-1186.

Kohsaka, S. *et al*, 2017. A method of high-throughput functional evaluation of EGFR gene variants of unknown significance in cancer. *Science translational medicine*, *9*(416), eaan6566.

Komite Penanggulangan Kanker Nasional, 2017. *Pedoman Nasional Pelayanan Kedokteran (PNPK): Kanker Paru.* Jakarta: Kementerian Kesehatan Republik Indonesia, 1-3.

Lamberti, G. *et al*, 2020. Beyond EGFR, ALK and ROS1: Current evidence and future perspectives on newly targetable oncogenic drivers in lung adenocarcinoma. *Critical reviews in oncology/hematology*, *156*, p.103119.

Lee, H. W., Park, Y. S., Park, S. & Lee, C. H., 2020. Poor prognosis of NSCLC located in lower lobe is partly mediated by lower frequency of EGFR mutations. *Scientific reports*, *10*(1), 1-8.

Liang, S. K., Ko, J. C., Yang, J. C. H. & Shih, J. Y., 2019. Afatinib is effective in the treatment of lung adenocarcinoma with uncommon EGFR p. L747P and p. L747S mutations. *Lung Cancer*, *133*, 103-109.

Lindeman, N. I. *et al*, 2018. Updated molecular testing guideline for the selection of lung cancer patients for treatment with targeted tyrosine kinase inhibitors: guideline from the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology. *Journal of Thoracic Oncology*, *13*(3), 323-358.

Liu, G. *et al*, 2020. 3D radiomics predicts EGFR mutation, exon-19 deletion and exon-21 L858R mutation in lung adenocarcinoma. *Translational lung cancer research*, *9*(4), 1212.

Malapelle, U. *et al*, 2021. Dealing with NSCLC EGFR mutation testing and treatment: A comprehensive review with an Italian real-world perspective. *Critical Reviews in Oncology/Hematology*, *160*, 103300.

McCourt, C.M. *et al*, 2013. Validation of next generation sequencing technologies in comparison to current diagnostic gold standards for BRAF, EGFR and KRAS mutational analysis. *PLoS One*, *8*(7), p.e69604.

Melosky, B. *et al*, 2022. Worldwide prevalence of epidermal growth factor receptor mutations in non-small cell lung cancer: a meta-analysis. *Molecular Diagnosis & Therapy*, *26*(1), pp.7-18.

Midha, A., Dearden, S. & McCormack, R., 2015. EGFR mutation incidence in non-small-cell lung cancer of adenocarcinoma histology: a systematic review and global map by ethnicity (mutMapII). *American journal of cancer research*, *5*(9), 2892.

Mitsudomi, T. *et al*, 2010. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. *The lancet oncology*, *11*(2), 121-128.

Mok, T. S. *et al*, 2017. Osimertinib or platinum–pemetrexed in EGFR T790M–positive lung cancer. *New England Journal of Medicine*, *376*(7), 629-640.

Mok, T. S. *et al*, 2009. Gefitinib or carboplatin–paclitaxel in pulmonary adenocarcinoma. *New England Journal of Medicine*, *361*(10), 947-957.

Monaco, S. E., 2012. Cytopathology of lung cancer: moving from morphology to molecular. *Diagnostic Histopathology*, *18*(8), 313-320.

Morgensztern, D. *et al*, 2012. Prognostic impact of malignant pleural effusion at presentation in patients with metastatic non–small-cell lung cancer. *Journal of thoracic oncology*, *7*(10), 1485-1489.

Mosesson, Y. & Yarden, Y., 2004. Oncogenic growth factor receptors: implications for signal transduction therapy. In *Seminars in cancer biology* (Vol. 14, No. 4, pp. 262-270). Academic Press.

Mulawarman, A., 2020. Ekspresi Serum miR-148 dan miR-155 Sebagai Kandidat Biomarker Prognosis Kanker Paru Jenis Karsinoma Bukan Sel Kecil (KPKBSK) Stage Lanjut di Indonesia Menggunakan Liquid Biopsy. *Disertasi*. Universitas Gadjah Mada, D.I. Yogyakarta.

Myers, D.J. & Wallen, J.M., 2022. Lung Adenocarcinoma [Updated 2022 Jun 21]. *Treasure Island (FL): StatPearls Publishing* [Diakses melalui: https://www.ncbi.nlm.nih.gov/boos/NBK519578/]

Nakamura, H. & Saji, H., 2014. A worldwide trend of increasing primary adenocarcinoma of the lung. *Surgery today*, *44*, 1004-1012.

Nakanishi, K., 1990. Alveolar epithelial hyperplasia and adenocarcinoma of the lung. *Archives of pathology & laboratory medicine*, *114*(4), 363-368.

Nakra, T. *et al*, 2020. Epidermal growth factor receptor mutation status in pulmonary adenocarcinoma: multi-institutional data discussion at national conference of "Lung Cancer Management in Indian context". *Current Problems in Cancer*, *44*(3), 100561.

Noronha, V. *et al*, 2013. EGFR mutations in Indian lung cancer patients: Clinical correlation and outcome to EGFR targeted therapy. *PLoS One*, *8*(4), e61561.

North, C. M. & Christiani, D. C., 2013. Women and lung cancer: what is new?. In *Seminars in thoracic and cardiovascular surgery* (Vol. 25, No. 2, pp. 87-94). WB Saunders.

O'Kane, G. M. *et al*, 2017. Uncommon EGFR mutations in advanced non-small cell lung cancer. *Lung Cancer*, *109*, 137-144.

Ortiz, A. F. H. *et al*, 2022. Clinical and CT patterns to predict EGFR mutation in patients with non-small cell lung cancer: a systematic literature review and meta-analysis. *European journal of radiology open*, 9, 100400.

Papadopoulos, A. *et al*, 2011. Cigarette smoking and lung cancer in women: results of the French ICARE case–control study. *Lung cancer*, *74*(3), 369-377.

Passaro, A. *et al*, 2021. Recent advances on the role of EGFR tyrosine kinase inhibitors in the management of NSCLC with uncommon, non-exon 20 insertions, EGFR mutations. *Journal of Thoracic Oncology*, *16*(5), 764-773.

Pelosi, G., Sonzogni, A. & Viale, G., 2010. The classification of lung carcinoma: time to change the morphology-based approach?. *International Journal of Surgical Pathology*, *18*(3), 161-172.

Qin, B. D. *et al*, 2018. The effectiveness of afatinib and osimertinib in a Chinese patient with advanced lung adenocarcinoma harboring a rare triple EGFR mutation (R670W/H835L/L833V): a case report and literature review. *OncoTargets and therapy*, 4739-4745.

Quan, X. *et al*, 2018. Epidermal growth factor receptor somatic mutation analysis in 354 Chinese patients with non-small cell lung cancer. *Oncology Letters*, *15*(2), 2131-2138.

Rizzo, S. *et al*, 2016. CT radiogenomic characterization of EGFR, K-RAS, and ALK mutations in non-small cell lung cancer. *European radiology*, *26*, 32-42.

Rizzo, S. *et al*, 2019. Genomics of non-small cell lung cancer (NSCLC): Association between CT-based imaging features and EGFR and K-RAS mutations in 122 patients—An external validation. *European journal of radiology*, *110*, 148-155.

Russo, A. *et al*, 2019. Heterogeneous responses to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in patients with uncommon EGFR mutations: new insights and future perspectives in this

complex clinical scenario. *International journal of molecular sciences*, *20*(6), 1431.

Sakurada, A., Shepherd, F. A. & Tsao, M. S., 2006. Epidermal growth factor receptor tyrosine kinase inhibitors in lung cancer: impact of primary or secondary mutations. *Clinical lung cancer*, *7*, S138-S144.

Sánchez-Ortega, M., Carrera, A. C. & Garrido, A., 2021. Role of NRF2 in lung cancer. *Cells*, *10*(8), 1879.

Santos, M. K. *et al*, 2014. Morphological computed tomography features of surgically resectable pulmonary squamous cell carcinomas: impact on prognosis and comparison with adenocarcinomas. *European Journal of Radiology*, *83*(7), 1275-1281.

Selamat, S. A. *et al*, 2011. DNA methylation changes in atypical adenomatous hyperplasia, adenocarcinoma in situ, and lung adenocarcinoma. *PloS one*, *6*(6), e21443.

Sequist, L. V. *et al*, 2006. Epidermal growth factor receptor mutation testing in the care of lung cancer patients. *Clinical cancer research*, *12*(14), 4403s-4408s.

Sequist, L. V. *et al*, 2011. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. *Science translational medicine*, *3*(75), 75ra26-75ra26.

Shah, R. & Lester, J. F., 2020. Tyrosine kinase inhibitors for the treatment of EGFR mutation-positive non–small-cell lung cancer: A clash of the generations. *Clinical lung cancer*, *21*(3), e216-e228.

Sharma, R., 2022. Mapping of global, regional and national incidence, mortality and mortality-to-incidence ratio of lung cancer in 2020 and 2050. *International journal of clinical oncology*, *27*(4), 665-675.

Sharma, S. V., Bell, D. W., Settleman, J. & Haber, D. A., 2007. Epidermal growth factor receptor mutations in lung cancer. *Nature Reviews Cancer*, *7*(3), 169-181.

Shepherd, F. A. *et al*, 2005. Erlotinib in previously treated non–small-cell lung cancer. *New England journal of medicine*, *353*(2), 123-132.

Shigematsu, H. *et al*, 2005. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. *Journal of the National Cancer Institute*, *97*(5), 339-346.

Sholih, M. G. *et al*, 2019. Risk factors of lung cancer in Indonesia: A qualitative study. *J. Adv. Pharm. Educ. Res/ Apr-Jun*, *9*(2), 41-45.

Sholl, L.M. *et al*, 2010. EGFR mutation is a better predictor of response to tyrosine kinase inhibitors in non–small cell lung carcinoma than FISH, CISH, and immunohistochemistry. *American journal of clinical pathology*, *133*(6), pp.922-934.

Socinski, M. A. *et al*, 2013. Treatment of stage IV non-small cell lung cancer: Diagnosis and management of lung cancer: American College of Chest Physicians evidence-based clinical practice guidelines. *Chest*, *143*(5), e341S-e368S.

Soh, J. *et al*, 2008. Sequential molecular changes during multistage pathogenesis of small peripheral adenocarcinomas of the lung. *Journal of Thoracic Oncology*, *3*(4), 340-347.

Sordella, R., Bell, D. W., Haber, D. A. & Settleman, J., 2004. Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. *Science*, *305*(5687), 1163-1167.

Sun, S., Schiller, J.H. & Gazdar, A.F., 2007. Lung cancer in never smokers–a different disease. *NatRev Cancer, 7*: 778–790.

Sun, Y. *et al*, 2010. Lung adenocarcinoma from East Asian never-smokers is a disease largely defined by targetable oncogenic mutant kinases. *Journal of clinical oncology*, *28*(30), 4616.

Sung, H. *et al*, 2021. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. *CA: a cancer journal for clinicians*, *71*(3), 209–249. https://doi.org/10.3322/caac.21660

Syahruddin, E. *et al*, 2018. Uncommon EGFR mutations in cytological specimens of 1,874 newly diagnosed Indonesian lung cancer patients. *Lung Cancer: Targets and Therapy*, pp.25-34.

Tamiya, Y. *et al*, 2023. Large-scale clinico-genomic profile of non-small cell lung cancer with KRAS G12C: Results from LC-SCRUM-Asia study. *Lung Cancer*, *176*, pp.103-111.

Tanaka, K. *et al*, 2016. Prognostic significance of aromatase and estrogen receptor beta expression in EGFR wild-type lung adenocarcinoma. *American Journal of Translational Research*, *8*(1), p.81.

Thorley, A. J. & Tetley, T. D., 2007. Pulmonary epithelium, cigarette smoke, and chronic obstructive pulmonary disease. *International journal of chronic obstructive pulmonary disease*, *2*(4), 409-428.

Tokudome, N. *et al*, 2020. Differential significance of molecular subtypes which were classified into EGFR exon 19 deletion on the first line afatinib monotherapy. *BMC cancer*, *20*(1), 1-8.

Tomashefski Jr, J. F. & Farver, C. F., 2008. Anatomy and histology of the lung. In *Dail and hammer's pulmonary pathology: Volume I: Nonneoplastic lung disease* (pp. 20-48). New York, NY: Springer New York.

Travis, W. D. *et al*, 2013. Diagnosis of lung cancer in small biopsies and cytology: implications of the 2011 International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society classification. *Archives of Pathology and Laboratory Medicine*, *137*(5), 668-684.

Travis, W. D. *et al*, 2015. Introduction to the 2015 World Health Organization classification of tumors of the lung, pleura, thymus, and heart. *Journal of Thoracic Oncology*, *10*(9), 1240-1242.

Travis, W. D., 2020. Lung cancer pathology: current concepts. *Clinics in chest medicine*, *41*(1), 67-85.

Tseng, C. H. *et al*, 2016. EGFR mutation and lobar location of lung adenocarcinoma. *Carcinogenesis*, *37*(2), 157-162.

Ueno, T. *et al*, 2012. Impact of age on epidermal growth factor receptor mutation in lung cancer. *Lung cancer*, *78*(3), 207-211.

Underwood, C. I. M., Musick, A. & Glass, C., 2019. Adenocarcinoma overview. https://www.pathologyoutlines.com/topic/lungtumoradenocarcinoma.html

Wang, Z. *et al*, 2018. Clinical and radiological characteristics of central pulmonary adenocarcinoma: a comparison with central squamous cell carcinoma and small cell lung cancer and the impact on treatment response. *OncoTargets and therapy*, *11*, 2509.

Wells, A., 1999. EGF receptor. *The international journal of biochemistry & cell biology*, *31*(6), 637-643.

Wu, J. Y. *et al*, 2008. Lung cancer with epidermal growth factor receptor exon 20 mutations is associated with poor gefitinib treatment response. *Clinical Cancer Research*, *14*(15), 4877-4882.

Wu, J. Y. *et al*, 2011. Effectiveness of Tyrosine Kinase Inhibitors on "Uncommon" Epidermal Growth Factor Receptor Mutations of Unknown Clinical Significance in Non–Small Cell Lung Cancer Uncommon EGFR Mutations. *Clinical cancer research*, *17*(11), 3812-3821.

Wu, S. G. *et al*, 2008. Frequent epidermal growth factor receptor gene mutations in malignant pleural effusion of lung adenocarcinoma. *European Respiratory Journal*, *32*(4), 924-930.

Wu, S. G. *et al*, 2017. Lung adenocarcinoma patients of young age have lower EGFR mutation rate and poorer efficacy of EGFR tyrosine kinase inhibitors. *ERJ Open Research*, *3*(3).

Wu, Y. L. *et al*, 2014. Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial. *The lancet oncology*, *15*(2), 213-222.

Xie, X. *et al*, 2022. Primary tumor location in lung cancer: the evaluation and administration. *Chinese Medical Journal*, *135*(02), 127-136.

Yang, J. C. *et al*, 2015. Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harboring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6. *The lancet oncology*, *16*(7), 830-838.

Yang, J. C. *et al*, 2020. Afatinib for the treatment of NSCLC harboring uncommon EGFR mutations: a database of 693 cases. *Journal of Thoracic Oncology*, *15*(5), 803-815.

Yatabe, Y., Kerr, K.M., Utomo, A., Rajadurai, P., Du, X., Chou, T.Y., Enriquez, M.L.D., Lee, G.K., Iqbal, J., Shuangshoti, S. and Chung, J.H., 2015. EGFR mutation testing practices within the Asia Pacific region: results of a multicenter diagnostic survey. *Journal of Thoracic Oncology*, *10*(3), pp.438-445.

Zhang, X. *et al*, 2006. An allosteric mechanism for activation of the kinase domain of epidermal growth factor receptor. *Cell*, *125*(6), 1137-1149.

Zhou, L., Li, H. & Yang, S., 2022. Age does matter in adolescents and young adults vs. older adults with lung adenocarcinoma: A retrospective analysis comparing clinical characteristics and outcomes in response to systematic treatments. *Oncology Letters*, *24*(4), 1-13.

Zhou, W. & Christiani, D. C., 2011. East meets West: ethnic differences in epidemiology and clinical behaviors of lung cancer between East Asians and Caucasians. *Chinese Journal of Cancer*, *30*(5), 287.